Tevogen Bio Holdings announced the enduring efficacy of its investigational COVID-19 treatment, TVGN 489, against the latest dominant SARS-CoV-2 strains, including the highly mutated JN.1 variant. TVGN 489, a pioneering allogeneic immunotherapy, utilizes Cytotoxic CD8+ T lymphocytes (CTLs) specifically tailored to combat SARS-CoV-2 in high-risk patients and those suffering from Long COVID.

Leveraging its unique mechanism that targets multiple SARS-CoV-2 proteins, TVGN 489 has demonstrated its robustness by retaining activity against all previously encountered COVID-19 strains. Recent surveillance underscores the treatment’s broad-spectrum efficacy, with 96% of its CTLs remaining active against current variants. This marks a significant stride in the ongoing battle against COVID-19 and its evolving mutations.

This announcement follows the positive outcomes from a Phase I study conducted in January 2023. In this study, high-risk patients infected with various COVID-19 variants, including delta and variants of omicron, witnessed significant clinical improvements and a dramatic reduction in viral load. The study showcased the safety and therapeutic potential of TVGN 489, with no significant adverse events reported.

Tevogen commits to further validating these promising results in advanced clinical trials while continuously monitoring the immunotherapy’s effectiveness against new SARS-CoV-2 strains. The company’s strategic focus on developing innovative treatments addresses the urgent need for effective COVID-19 interventions, particularly for patients at high risk of severe outcomes and those grappling with Long COVID.

TVGN 489 leverages the ExacTcell platform to identify numerous viral genome peptides as CTL targets, offering a comprehensive approach to viral combat by targeting the entire COVID-19 genome instead of solely focusing on the Spike protein. This broad target spectrum has ensured the persistence of T-cell targets across the various stages of viral evolution, reducing the need for frequent formulation adjustments—an advantage over treatments like monoclonal antibodies, which have witnessed a rapid loss of targets due to mutations. This breakthrough represents a hopeful advancement in Tevogen Bio’s efforts to provide lasting solutions to the challenges posed by COVID-19.

Source link: http://www.businesswire.com/news/home/20240320704564/en/Tevogen-Bio-Reports-Its-Investigational-SARS-CoV-2-Specific-T-Cell-Therapy-TVGN-489-Retains-Activity-Against-the-Dominant-JN.1-Variant

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.